The following is a list of materials I have read and collected over the past several years.  They include primarily first-source peer reviewed research in the fields of neurobiology, psychiatry and the like.  The also include editorials that draw conclusions from this research, as well as articles written by persons with lived experiences of emotional distress about their own encounters with psychiatry and mental health.

Please Note:  Each item includes a hyperlink to the full text original source.

Intro: The Summary Case against Current Use Models

  1. Comprehensive Bibliography/Literature Review of Evidence Against the Efficacy of Long Term Use of Neuroleptics, Antidepressants and Benzodiazepines
  2. Rethinking Psychiatric Care: If We Follow the Scientific Evidence, What Must We Do to Better Promote Long-term Recovery?
  3. When Treatment Might Cause Harm: Exploring Ethical Dilemmas Related to Diagnosis, Drugs, and Other Possibly Iatrogenic Aspects of Mental Health Care
  4. The Crumbling Pillars of Behavioral Genetics

Section One: Psychosis and Typical & Atypical Neuroleptics

  1. (1967) One Year After Discharge: Community Adjustment of Schizophrenic Patients
  2. (1975) Comparison of Two Five-Year Follow-Up Studies: 1947 to 1952 and 1967 to 1972
  3. (1977) Maintenance Antipsychotic Therapy: Is the Cure Worse than the Disease?
  4. (1978) Dopaminergic Supersensitivity After Neuroleptics: Time-Course and Specificity
  5. (1978) Neuroleptic-Induced Supersensitivity Psychosis
  6. (1978) Are the Schizophrenics for Whome rugs May be Unnecessary of Contraindicated?
  7. (1987) The Vermont Longitudinal Study of Persons with Severe Mental Illness, II: Long-Term Outcome of Subjects Who Retrospectively Met DSM-III Criteria for Schizophrenia
  8. (1992) The International Pilot Study of Schizophrenia: Five-Year Follow-Up Findings
  9. (1994) Empirical Correction of Seven Myths About Schizophrenia with Implications for Treatment
  10. (1994) One Hundred Years of Schizophrenia - A Meta-Analysis of the Outcome Literature
  11. (1997) Clinical Risk Following Abrupt and Gradual Withdrawl of Maintenance Neuroleptics
  12. (1998) Subcortical MRI Volumes in Neuroleptic-Naive and Treated Patients with Schizophrenia
  13. (1999) The Neuropathological Effects of Antipsychotic Drugs
  14. (2003) Treatment of Acute Psychosis Without Neuroleptics: Two-Year Outcomes from the Soteria Project
  15. (2003) Half a Century of Antipsychotics and Still a Central Role for Dopamine D2 Receptors
  16. (2003) Myers v State of North Carolina - Analysis of the Olanzapine Clinical Trials - Dangerous Drug, Dubious Efficacy
  17. (2005) Dopamine Supersensitivity correlates with D2High states, implying many paths to psychosis
  18. (2005) Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
  19. (2005) Influence of Chronic Exposure to Antipsychotic Medications on Brain Size before and after Tissue Fixation - A Comparison of Haloperidol and Olanzapine in Macaque Monkeys
  20. (2006) Prejudice and Schizophrenia: A Review of the "Mental Illness is Just Like Any Other Illness" Approach
  21. (2006) Does Antipsychotic Withdrawl Provoke Psychosis
  22. (2006) RCT Quality of Life Differences on First v Second Generation Antipsychotics
  23. (2006) Effect of Chronic Exposure to Antipsychotic Medication on Cell Numbers in the Parietal Cortex of Macaque Monkeys
  24. (2006) Oxford University Press Association of Physicians - Why are We Still Prescribing Neuroleptics
  25. (2007) The Effect of Atypical Versus Typical Antiypsychotics on Tardive Dyskinesia
  26. (2007) “Breakthrough” Dopamine Supersensitivity during Ongoing Antipsychotic Treatment Leads to Treatment Failure over Time
  27. (2007) Factors Involed in Outcome and Recovery in Schizophrenia Patients Not on Antipsychotic Medications: A 15-year Multifollow-up Study (Harrow Study)
  28. (2007) Robert Whitaker Sworn Affidavit - Overview of Research Literature on Schizophrenia and Antipsychotic Medication
  29. (2008) Critique of the Dopamine Hypothesis
  30. (2008) Atypical Antipsychotic Agents for the Schizophrenia Prodrome - Not a Clear First Choice
  31. (2008) Double Blind Comparison of First and Second Generation Antipsychotics in Early-Onset Schizophrenia and Schizoeffective Disorder
  32. (2008) Grace Jackson MD Sworn Affidavit - Evidence for the Neurotoxicity of Antipsychotic Drugs
  33. (2010) Incidents of Tardive Dyskinesia with Atypical v Conventional Antipsychotic Medications - A Prospective Cohort Study
  34. (2011) Long-term Antipsychotic Treatment and Brain Volumes
  35. (2011) Cross-National Clinical and Functional Remission Rates: Worldwide Schizophrenia Outpatient Health Outcomes (W-SOHO) Study
  36. (2011) The Rise and Fall of Atypical Antipsychotics (British Journal of Psychiatry Editorial)
  37. (2012) Structural and Functional Brain Changes in First Episode Psychosis and the Effects of Antipsychotic Medication
  38. (2012) Extrapyramidal motor side-effects of First and Second Generation Antipsychotics
  39. (2013) Life Expectancy and Death by Diseases of the Circulatory System in Patients with Bipolar Disorder or Schizophrenia in Nordic Countries
  40. (2013) Magic Bullets for Mental Disorders: The Emergency of the Concept of an "Antipsychotic" Drug
  41. (2013) The Myth of Schizophrenia as a Progressive Brain Disease
  42. (2013) Progressive Brain Changes in Schizophrenia related to Antipsychotic Treatment? A Meta-Analysis of Longitudinal MRI Studies
  43. (2013) Recovery in Remitted First-Episode Psychosis at 7 Years of Follow-up of an Early Dose Reduction/Discontinuation of Maintenance Treatment Strategy: Long-term Follow-Up of a 2-year Randomized Clinical Trial
  44. (2013) Antipsychotics and Brain Shrinkage - An Update
  45. (2014) Harrow 20-year results: Does Treatment of Schizophrenia with Antipsychotic Medications Eliminate or Reduce Psychosis?
  46. (2015) Lack of Evidence for Region Brain Volume or Cortical Thickness Abnormalities in Youths at Clinical High Risk for Psychosis:  Findings from the Longitudinal Youth Risk Study (Abstract Only, Full text requires Journal Subscription)
  47. (2015) Treatment of Young People with Antipsychotic Medications in the United States

Section Two: Depression & Mood Disorders vs Antidepressants, Stabilizers and Benzodiazepines

  1. (1964) The Therapeutic Efficacy of Antidepressant Drugs
  2. (1979) Judgment of Contingency in Depressed and Nondepressed Students: Sadder but Wiser?
  3. (1980) Social Competence and Depression: The Role of Illusory Self-Perceptions
  4. (2002) Antidepressants and Placebos: Secrets, Revelations, and Unanswered Questions
  5. (2002) The Emperor’s New Drugs: An Analysis of Antidepressant Medication Data Submitted to the U.S. Food and Drug Administration
  6. (2002) Antidepressants: A Triumph of Marketing over Science
  7. (2003) Can Long-Term Treatment with Antidepressants Worsen Depression
  8. (2005) Serotonin and Depression: A Disconnect Between the Advertisements and the Scientific Literature
  9. (2006) The Sham ECT Literature: Implications for Consent to ECT
  10. (2006) Do Antidepressants Cause or Cure Abnormal Brain States
  11. (2008) Initial Severity and Antidepressant Benefits: A Meta-Analysis of Data Submitted to the Food and Drug Administration
  12. (2008) Psychotherapy for Depression in Adults: A Meta-Analysis of Comparative Outcome Studies
  13. (2010) Sequenced Treatment Alternatives to REleive Depression STAR*D Review
  14. (2011) STAR*D A Tail and Trail of Bias
  15. (2011) Blue Again: Perturbational Effects of Antidepressants Suggest Monoaminergic Homeostasis in Major Depression
  16. (2011) Tardive Dysphoria: The Role of Long Term Antidepressant Use in Inducing Chronic Depression
  17. (2011) The Persistence of Sexual Dysfunction Side Effects after Discontinuation of Antidepressant Medications
  18. (2012) Letter to [Journal] Editor - Patient Online Report of SSRI-Induced Persistent Postwithdrawal Anxiety and Mood Disorders
  19. (2014) Outcome of Mood Disorders Before Psychopharmacology: A Systematic Review
  20. (2014) Paroxetine vs. Placebo - Analysis of Change on Hamilton Rating Scale
  21. (2014) The Medicalization of "Ups and Downs:" the Marketing of the New Bipolar Disorder
  22. (2014) Potential Antidepressant Overtretament Associated with Office Use of Brief Depression Symptom Measures
  23. (2015) Withdrawal Symptoms after Selective Serotonin Reuptake Inhibitor Discontinuation: A Systematic Review
  24. (2015) The Intergenerational Transmission of Anxiety: A Children-of-Twins Study
  25. (2015) Empirically Derived Criteria Cast Doubt on the Clinical Significance of Antidepressant-Placebo Differences (Abstract, Full Text $39.95)

Section Three: Critical Analysis of the Pharmaceutical Industry’s Research and Marketing Practices

  1. (2003) Psychology in the Prescription Era: Building a Firewall Between Marketing and Science
  2. (2006) Financial Ties Between DSM-IV Panel Members and the Pharmaceutical Industry
  3. (2006) The Promotion of Gabapentin: An Analysis of Internal Industry Documents
  4. (2008) Selective Publication of Antidepressant Trials and Its Influence on Apparent Efficacy
  5. (2009) The Promotion of Olanzapine in Primary Care: An Examination of Internal Industry Documents
  6. (2009) The Pharmaceutical Industry and the Construction of Psychiatric Diagnoses
  7. (2010) Shadow Science: Zyprexa, Eli Lilly and the Globalization of Pharmaceutical Damage Control
  8. (2010) From Evidence-Based Medicine to Marketing-Based Medicine - Evidence from Internal Industry Documents
  9. (2012) Conflict of Interest Reporting by Authors Involved in Promotion of Off-Label Drug Use: An Analysis of Journal Disclosures
  10. (2012) Why Most Biomedical Findings Echoed by Newspapers Turn Out to be False: The Case of Attention Deficit Hyperactivity Disorder
  11. (2013) Pharmaceuticals, Political Money, and Public Policy: A Theoretical and Empirical Agenda
  12. (2013) Institutional Corruption of Pharmeceuticals and the Myth of Safe and Effective Drugs
  13. (2013) Five Un-Easy Pieces of Pharmaceutical Policy Reform
  14. (2013) Corruption of Pharmaceutical Markets: Addressing the Misalignment of Financial Incentives and Public Health
  15. (2015) Research Misconduct Identified by the US Food and Drug Administration: Out of Sight, Out of Mind, Out of Peer-Reviewed Literature

Section Four: Institutional Criticism of the Mental Health System & the Biomedical Model, with Testimony from Psychiatric Survivors as well as Professionals

  1. (1977) The Need for a New Medical Model: A Challenge for Biomedicine
  2. (2007) Toward a Participatory and Risk-Limiting Approach to Neuroleptic Drugs
  3. (2009) On the Brain Disease Model of Mental Disorders
  4. (2010) Psychiatric Diagnosis as a Political Device
  5. (2011) A Critical Review of the First 10 Years of Candidate Gene-by-Environment Interaction Research in Psychiatry
  6. (2012) Editorial Policy on Candidate Gene Association
  7. (2012) Psychiatry Beyond the Current Paradigm
  8. (2013) The Side Effects of Medicalization - A Meta-Analytic Review of How Biogenetic Explanations Affect Stigma
  9. (2013) The Biomedical Model of Mental Disorder: A Critical Analysis of its Validity, Utility and Effects on Psychotherapy Research
  10. (2013) Division of Clinical Psychology Position Statement on the Classification of Behavior and Experience in Relation to Functional Psychiatric Diagnosis
  11. (2013) Five Decades of Gene Finding Failures
  12. (2014) Critique of Genetic Research:  Expensive Castles in the Air
  13. (2014) Does Long Term Antipsychotic Use Lead to Worse Outcomes?
  14. (2014) Effects of a Chemical Imbalance Causal Explanation on Individuals' Perceptions of Their Depressive Symptoms
  15. Anti-Authoritarians and Psychosis - Do they Do Better? 
  16. Avoiding Voices as Bad as Listening Too Much
  17. DSM-V Diagnosed in Stinging Rebuke
  18. Interpreting Harrow - Are Drugs to Blame?
  19. Poverty and Mental Illness are Linked
  20. Reviving the Myth of Mental Illness
  21. Why Anti-Authoritarians are Diagnosed as Mentally Ill